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SBackground:During lobectomy, resection of pulmonary artery, followed by reconstruction or replacement with
or without concomitant sleeve bronchial resection, is feasible in selected cases. We report morbidity, mortality,
and technical issues in pulmonary artery replacement using a cryopreserved arterial allograft after sleeve
resection for centrally located non–small cell lung carcinoma (NSCLC).
Methods: We reviewed clinical and pathologic data of patients who underwent arterial sleeve lobectomy with
pulmonary artery replacement in our institution from 2007 to 2012.
Results:Of 178 centrally located NSCLCs, sleeve resections were performed in 92 (51%), pneumonectomies in
33 (18%), and lobectomies in 53 (31%). Of the 32 (34.7%) pulmonary) reconstructions (excluding tangential
suture), 20 (21.7%) were end-to-end anastomosis, 2 (2.1%) were pericardial patch reconstructions, and 10
(11%) were PA replacements. Clinical T staging was cT2a in 4 patients, cT2b in 3, cT3 in 2, and cT4 in 1.
Four patients received concurrent induction chemoradiotherapy. Three patients underwent a double-sleeve right
lobectomy. Cryopreserved allografts used were descending thoracic aorta (n ¼ 3) and pulmonary arteries
(n ¼ 7). Complete resection (R0) was achieved in all patients. Final N staging was pN0 (n ¼ 4), pN1
(n¼ 5), and pN2 (n¼ 1). There was no operative mortality. Four patients had major morbidity, including 1 early
conduit thrombosis treated by pneumonectomy completion. Graft patency, assessed by contrast-enhanced
computed tomography scan, was 90%. Mean follow-up was 25  14 (range, 8-47) months (30% for>36
months). Overall 5-year survival was 66.7%, and the estimated median disease-free survival was 42 months.
Conclusions: In central NSCLCs, conservative surgery using a cryopreserved arterial allograft to replace the
pulmonary artery after extended segmental resection could avoid pneumonectomy in selected patients. (J Thorac
Cardiovasc Surg 2013;146:1191-7)GSleeve resection has several advantages over pneumonec-
tomy for centrally located primary non–small cell lung car-
cinoma (NSCLC): fewer postoperative complications,1-4
reduced loss of pulmonary function,5 improved sur-
vival,1,3,5,6 better completion of adjuvant treatment,3 and
higher quality of life.7 Sleeve resection is an appealing pro-
cedure for patients with impaired lung function or high
operative risk.8 It has also been considered the better option
to avoid the morbidity and mortality related to pneumo-
nectomy.1,2,6,9,10 Depending on pulmonary) involvement,
reconstruction ranges from tangential suture to patch
reconstruction, end-to-end anastomosis, and, finally, PA
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The Journal of Thoracic and Caris indicated when the length between the 2 disease-free arte-
rial PA stumps (proximal and distal) precludes reconstruction
by end-to-end anastomosis. Numerous synthetic12 and
autologous or heterologous biologic materials10,11,13,14
have been used in this procedure. The material selected
depends on the location and extent of the arterial defect,
together with the experience of the surgical team.
We report herein our experience in pulmonary sleeve
resection in centrally located NSCLCs using a cryopre-
served arterial allograft for PA replacement, alone or in as-
sociation with a bronchial sleeve, as a suggested alternative
to pneumonectomy.METHODS
Patients
Of 178 patients with centrally located NSCLCs consecutively treated in
our institution between January 2007 and December 2012, 92 (51.5%)
were amenable to circumferential arterial and/or bronchial sleeve resec-
tions, 33 (18.5%) underwent pneumonectomy, and 53 (30%) were finally
resected by lobectomy (tangential PA resections and bronchial wedge were
considered variations of standard lobectomy). PA reconstruction by autol-
ogous pericardial patch was performed in 2 cases, but end-to-end anasto-
mosis was preferred when PA invasion was not amenable to tangential
resection. Patients with extensive PA involvement, requiring cryopreserved
allograft reconstruction, were included in the present study (Table 1).
Extensive invasion was defined as full-thickness PA wall invasion closediovascular Surgery c Volume 146, Number 5 1191
Abbreviations and Acronyms
CT ¼ computed tomography
NSCLC ¼ non–small cell lung carcinoma
PA ¼ pulmonary artery
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Sto the first division of the segment proximal to the origin of the superior
segmental artery (A6) of the lower lobes, or immediately below it. The
invasion was ascertained by the definitive pathologic examination. Three
patients presenting with direct invasion of intrapericardial PA, requiring
cardiopulmonary bypass, were excluded from the study.
All cases meeting oncologic and functional criteria of European
Respiratory Society and European Society of Thoracic Surgeons
guidelines15 were discussed by a multidisciplinary team (including
L.M. and A.G-C.). Final staging was assessed according to the 2009
International Association for the Study of Lung Cancer staging system.
Written informed consent was obtained for all patients. This study was
approved by our institutional review board and ethics committee.
Preoperative Assessment and Eligibility
Preoperative evaluation included chest X-ray film, bronchoscopy,
18F-fluoro-D-glucose positron emission tomography, and total-body contrast-
enhanced computed tomography (CT) scan. Clinical staging followed the
revised TNM system, published in 2009, by the International Association
for the Study of Lung Cancer.
In the case of clinical suspicion of N2 disease (lymph node short axis>1
cm on CT scan or 18F-fluoro-D-glucose positron emission tomography up-
take maximum standardized uptake value>2.5), histologic confirmation
was assessed by the most appropriate invasive methods. If N2 disease
was confirmed, neoadjuvant platinum-based chemotherapy and concurrent
radiotherapy (45-60 Gy) were delivered to the tumor and mediastinalTABLE 1. Clinical characteristics, procedure, and outcomes in patients un
Patient
Oncologic status
NSCLC Surger
No. Age/sex TNM
CRT
Gray timing, wk
Surger
lobectomy–CAA
resectio
1 70/M cT2N0M0/pT2N0M0 — LUL-thoracic aorta al
2 59/M cT2N0M0/pT3N1M0 — LUL-thoracic aorta al
3 61/M cT2N0M0/pT2N0M0 — LUL-pulmonary artery
4 34/F cT2N1M0/pT2N1M0 — LUL-thoracic aorta al
5 63/M cT4N0M0/pT4N0M0 — LUL-pulmonary artery
6 47/M cT2N2M0/pT2N1M0 60 Gy,
8
LUL-pulmonary artery
7 68/M cT2N2M0/pT2N2M0 60 Gy,
8
RUL (DS)-pulmonary
8 78/M cT3N0M0/pT3N0M0 — LUL-pulmonary artery
9 61/M cT3N2M0/pT3N1M0 45 Gy,
12
RUL (DS)-pulmonary
superior vena cava
10 58/F cT2N2M0/pT2N1M0 60 Gy,
8
RUL (DS)-pulmonary
Dashes indicate the patients did not receive radiotherapy. NSCLC, Non–small cell lung ca
LUL, left upper lobe; NED, alive, no evidence of disease; RUL, right upper lobe; DS, dou
1192 The Journal of Thoracic and Cardiovascular Surtargets. Patients were considered operable in the presence of a clinical
response on chest CT scan. When persistence of cN1 or cN2 disease was
suspected, mediastinal restaging was performed. In case of progressive
or N2 disease at restaging, surgical intervention was discarded.
Resection was considered functionally possible if the predictive postop-
erative forced expiratory volume in 1 second, calculated on the basis of
spirometry and isotopic scanning, was more than 40% of the predicted
value and there was no major hypoxemia (<60 mm Hg) or hypercapnia
(>46 mm Hg).15 All patients selected for PA replacement would have
been expected to tolerate pneumonectomy.
Surgical Technique
All patients underwent double-lumen endotracheal intubation. The sur-
gical approach was standard posterolateral thoracotomy. An intercostal
muscle flap was harvested and preserved if bronchovascular reconstruction
was planned. No irreversible procedure was performed before thoracic
cavity exploration and confirmation of resectability by frozen section
analysis. Oncologic and technical feasibility of sleeve resection and
modality of PA reconstruction were assessed by the surgeon (A.G-C.) after
proximal (most often intrapericardial) and distal control in the fissure. The
proximal extension of the tumor always required controlling the PA origin,
either proximal control posterior to the mobilized vena cava on the right
side or proximal to the divided ligamentum arteriosum on the left side.
Recurrent laryngeal and vagus nerves were identified routinely and
preserved if oncologically possible.
The superior pulmonary vein was divided, allowing satisfactory expo-
sure of the proximal PA. Systemic heparin sodium (5000 U/h) was intrave-
nously administered before PA clamping (Figure 1, A). Vascular clamps
were placed at the proximal and distal disease-free PA segment. En bloc
resection of the tumor, upper lobe, and PA and, if required, adjacent struc-
tures (pericardium, chest wall, and bronchus circumference) was per-
formed. The central extent of the PA resection was placed at least 5 mm
away from the proximal clamp to ensure the ability to properly suture.dergoing lobectomy with pulmonary artery replacement
y Complications Outcome
y
-associated
n
Major
complications
Minor
complications
Survival,
mo, status
lograft — — 47, NED
lograft — Sputum
retention
42, NED
allograft Pneumopathy — 23, Deceased
(metastatic disease)
lograft CAA thrombosis — 44, NED
allograft — — 24, NED
allograft — — 21, NED
artery allograft — — 8, NED
allograft Empyema,
pneumopathy
Sputum
retention
6, Deceased
(retroperitoneal
hematoma)
artery allograft,
replacement
— — 18, NED
artery allograft Pneumopathy — 20, NED
rcinoma; CRT, induction chemoradiotherapy; CAA, cryopreserved arterial allograft;
ble sleeve; TNM, tumor nodes metastasis classification.
gery c November 2013
FIGURE 1. Surgical technique. A, Right upper lobe tumor involving the pulmonary artery (PA). Complete mobilization of the superior vena cava is needed
before proximal PA control. To provide full exposure, the first steps are proximal and distal PA crossclamping using Satinsky and bulldog clamps,
respectively, combined with division of the superior pulmonary vein. B, In the case of double sleeve, bronchial anastomosis is performed first, using a hybrid
technique,3 and checked before PA reconstruction. C, Proximal ‘‘end-to-end’’ anastomosis between cryopreserved allograft and PA stump is performed with
a nonabsorbable running suture. Corner sutures were used as a landmark to avoid twist. D, End-to-end distal anastomosis is performed after proximal PA
reclamping, with or without distal clamp, and checked using the backflow.
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analysis. After resection, if the distal disease-free PA stumpwas too short to
allow both clamping and anastomosis, we removed the distal clamp
because the surgical atelectasis of the remaining lobe progressively
reduced the blood backflow (the lower pulmonary vein also might be
clamped as needed). If complete resection required vascular and bronchial
sleeves (double sleeve, n ¼ 3), the bronchial anastomosis was performed
first, using a hybrid technique3 (Figure 2, B).
Cryopreserved Arterial Allografts
Grafts originated from multiorgan donors whose PA and thoracic aorta
were harvested, assessed, cryopreserved, and packed, as previously
described,16 by the Transplant Service Foundation (Hospital Clinic,
Barcelona, Spain). On removal from liquid nitrogen, the cryopreserved
arterial allograft was placed in dry ice (80C), sent to the operating room,
and thawed (containers placed in a 37C water bath for approximately
10 minutes).11,17 After washing in saline for 5 minutes, the allograft was
then ready for implantation; ABO blood group and human leucocyte
antigen group compatibility was not required. Morphologic criteria, based
on preoperative chest CT scan (location, length, and diameter of the vessel
to be replaced), were used to select the appropriate graft. Until 2008, we
used the thoracic aorta because it was the only cryopreserved allograft
available to us. When PA allografts became available in our tissue bank,
they were routinely used.The Journal of Thoracic and CarArterial Allograft Implantation
The anastomosis was performed under systemic heparinization and with
irrigation using local heparinized saline. The systemic anticoagulation was
not reversed with protamine, to avoid in situ thrombosis. The selected cry-
opreserved allograft was cut as short as possible, to avoid kinking of the
graft during reexpansion of the pulmonary parenchyma. Before anasto-
mosis, corner sutures were used as landmarks to avoid twist. End-to-end
anastomosis between the proximal PA stump and the graft was performed
first, using 5/0 polypropylene running sutures (Figure 1, C). To avoid
excess length and kinking, the proper graft length was determined under
blood pressure after proximal PA declamping and distal graft crossclamp-
ing. After proximal PA reclamping, the distal part of the cryopreserved
allograft was then approximated to the distal PA stump with running su-
tures; the graft was flushed with heparinized saline and filled with blood
backflow immediately before completing the suture (Figures 1, D, and 2,
C). The proximal clamp was then removed while a gentle ventilation of
the remaining lobe quickly enhanced lung perfusion. A pedicled flap was
used to wrap the bronchial stump/anastomosis and separate vascular and
bronchial sutures.
Postoperative Care Follow-up
All patients were promptly extubated in the operating room (or in the
intensive care unit). Patients received postoperative thromboembolic pro-
phylaxis with low-molecular-weight heparin for 3 weeks. Survival, tumordiovascular Surgery c Volume 146, Number 5 1193
FIGURE 2. A, Chest computed tomography showing a central tumor with large invasion of the left pulmonary artery (PA). The PA involvement extended
from the A1 origin to beneath the A6 branch. B, Left pulmonary artery proximal disease-free stump (5-mm length) and cryopreserved allograft are sutured
together with a running polypropylene 5/0 suture. C, Cryopreserved allograft is filled with heparinized saline, before starting backflow and flushing out the
air bubbles. Perfect matching is observed between the cryopreserved allograft and native PA diameters. Allograft length must be as short as is feasible to
avoid kinking after lung reallocation in the thoracic cavity. D, Postoperative coronal color-code perfusion iodine map showing patent PA and branches into
the well-expanded lower lobe.
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Srecurrence, and graft patency were assessed during follow-up. A chest CT
scan (with a bolus injection of contrast medium and multiplanar recon-
struction to assess graft patency) and an additional abdominal and brain
CT scan were scheduled every 3 months for the first 2 years, and every
6 months for 5 years thereafter.
Results are expressed as means  SDs. Survival probabilities from the
surgery date until death were calculated using the Kaplan-Meier method,
and estimated median disease-free survival (months) was calculated from
the day of surgery until any oncologic event related to NSCLCs.RESULTS
Patient and TNM Status
Between January 2007 and December 2012, 92 (51%) of
178 central NSCLC tumors were amenable to circumferen-
tial arterial and/or bronchial sleeve resection, 33 (18%)
required pneumonectomy, and 53 (31%) were resected by
lobectomy. Reconstruction was performed in 32 (35%) of
the patients: 2 (2.2%) by autologous pericardium patch,
20 (22%) by end-to-end anastomosis, and 10 (10.8%) by
PA replacement by cryopreserved arterial allograft. Patients
who underwent PA replacement were 8 men and 2 women,
with a mean age of 62 12.4 (range, 34-78) years (Table 1).
Of these patients, 3 were older than 70 years, 7 were
smokers, and 4 had a history of pulmonary disease. Tumor
histologic features included 7 squamous cell carcinomas,
2 adenocarcinomas, and 1 atypical carcinoid tumor. The1194 The Journal of Thoracic and Cardiovascular Surmean forced expiratory volume in 1 second was 2.2  0.4
(range, 1.6-2.6) L; 4 patients had a forced expiratory vol-
ume in 1 second of less than 60%. All patients had a PA
patency despite massive tumor involvement.
In all cases, PA angioplasty or replacement was
considered when analyzing the preoperative chest CT
scan (Figure 2, A). During the same study period, a cryopre-
served allograft was available in the operating room, but
was not used in 23 cases because pneumonectomy or
simpler PA reconstruction was achieved.
Preoperative staging identified cN0 disease in 5 patients
and cN1 disease in 1; the indication for induction chemora-
diotherapy was N2 disease in 4 patients. Clinical T staging
was cT2a in 4 patients, cT2b in 3, cT3 in 2, and cT4 in 1
because of invasion of the superior vena cava. The mean
size of tumors was 49.8  12.9 (range, 30.5-75) mm. A
chest CT scan after induction chemoradiotherapy showed
partial responses in all cases.
Type of Resection and Reconstruction
Seven procedures were performed on the left side and 3
on the right side. Double-sleeve lobectomy was performed
in 3 patients. A frozen section of the arterial wall was
positive in 4 cases, requiring enlargement of the resection
during the same operative procedure. During the samegery c November 2013
FIGURE3. Kaplan-Meier curve for overall survival in 9 patients with pat-
ent pulmonary artery reconstruction.
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a positive distal margin that precluded lobe-sparing
surgery, and they underwent pneumonectomy. A pulmonary
cryopreserved allograft was used in all but 3 procedures
(patients 1, 2, and 4, in whom PAwas replaced by an aortic
allograft). The mean procedure duration was 210  37
(range, 177-287) minutes. Complete resection (R0) was
achieved in all patients; final pN0 was identified in 4
patients, pN1 in 5, and pN2 in 1. Five patients (2, 4, 5, 7,
and 8) received postoperative chemotherapy.
Postoperative Course
There were no hospital deaths. Five patients (2-4, 8, and
10) sustained morbidity, including 4 major and 2 minor
complications (Table 1). Patient 4 required prompt comple-
tion pneumonectomy because of thrombosis of the allograft
on the first postoperative day. Cryopreserved allograft
patency was 90% (9/10). Postoperative pneumopathy
associated with empyema required a chest tube placement
in patient 8. All patients required an intensive care unit
stay, with a median of 3.6 (range, 1-23) days; the length
of hospital stay was 11  6.7 (range, 9-27) days.
Follow-up
No patients were lost to follow-up. The median time of
observation was 25  14 (range, 8-47) months (30% for
>36 months), and 7 patients are still alive with no evidence
of recurrence (Figure 3). Patient 8 died of complications of
a massive spontaneous retroperitoneal hematoma at 6months
after surgery, and patient 3 died of metastatic disease at 22
months (Table 1). A follow-up CT scan showed no signs of
allograft infection, aneurismal degeneration, calcification,
or surrounding tissue infiltration (Figure 2, D). Combined
bronchial anastomosis (patients 7, 9, and 10) produced no
early (kinking)ordelayedabnormality (stenosis orgranuloma
formation). The Kaplan-Meier survival curve shows that
overall 5-year survival was 66.7% (Figure 3); the median
estimated disease-free survival was 42 months (patient 4 is
excluded because of completion pneumonectomy).
DISCUSSION
The present study reports our experience with sleeve PA
resection in patients with extensive PA invasion by NSCLC.
Replacing the native vessel with a cryopreserved allograft
demonstrated that this lung parenchyma-sparing procedure
is feasible, with acceptable morbidity and no mortality.
Our group considers that avoidance of pneumonectomy is
essential to decrease early postoperative mortality and
improve the patient’s quality of life and long-term out-
comes.3,7,18 A meta-analysis by Ferguson and Lehman18 of
early-stage NSCLC compared outcomes after 860 sleeve
resections and 746 pneumonectomies. The sleeve group had
better long-term survival and quality of life, regardless of
underlying cardiopulmonary function.18Ma and coworkers19The Journal of Thoracic and Carconcluded that, despite PA reconstruction, sleeve resection
offered better long-term survival than did pneumonectomy.
In the setting of major lung resection, the incidence of sleeve
resection remains low, and is even lower in arterial reconstruc-
tion,with reported rates ranging from1.5% to 3.7%.2,9,20The
most common arterial reconstructions described by surgical
teams are tangential suture, angioplasty by patch, and end-
to-end anastomosis; the latter often represents the last effort
before pneumonectomy is indicated (Table 2). When the
extent of the PA defect precludes end-to-end anastomosis,
some surgical teams planned PA replacement.11,16 However,
experienced lung preservation surgery units either did not
perform PA replacement6,8,20 or did so anecdotally.10
Prosthetic and biological substitutes have been used for
this purpose. Prosthetic materials (polytetrafluoroethylene
[Dacron]; Gore-Tex, WL Gore & Associates, Flagstaff,
Ariz)12 have been occasionally used12,21; they are readily
available, are easy to use, and can be adjusted perfectly to
the PA diameter. The main issues of these substitutes are
the high frequency of early thrombosis21 and potential infec-
tious complications, especially in the case of double-sleeve
resection, and the need for long-term anticoagulation ther-
apy. Biologic substitutes are arterial or venous allografts
or autologous pericardium conduits used with satisfactory
results by Rendina and coworkers11 in 3 PA replacements.
Homologous saphenous22 or pulmonary veins23 are possible
alternatives. However, they require time-consuming intrao-
perative procedures, produce variable outcomes related to
graft shrinkage or twisting,23 and are not always available.
Cryopreserved arterial allografts offer substantial advan-
tages: availability in tissue banks, bacteriologic safety, and
no need for anticoagulation therapy. Their ability to resist
infection has been demonstrated by vascular surgeons in
the routine use of cryopreserved allografts to address aortic
prosthesis infection. The main drawbacks are related to
availability and the need for an appropriate surgical
structure, regular harvesting of organs, and coordinationdiovascular Surgery c Volume 146, Number 5 1195
TABLE 2. Pulmonary artery reconstruction by different techniques (tangential suture, patch, end-to-end anastomosis, and replacement by
conduits)
Source Period, y No. TS/P/EE/C Conduit type Mortality/PA thrombosis 5-y Survival,%
Rendina and colleagues,14 (1999) 7 52 -/34/15/3 HPP/APP -/1 38
Shrager and colleagues,27 (2000) 7 33 19/11/3/0 — -/- 48
Fadel and colleagues,2 (2002) 20 11 -/-/11/- — 1 (0.7)/- 52
Lausberg and colleagues,28 (2005) 7 67 27/1/39/- — 1 (1.5)/- 43
Cerfolio and Bryant,20 (2007) 8 42 31/7/4/- — 1 (2.3)/- 60
Alifano and colleagues,9 (2009) 8 93 90/-/3/- — 5 (5.4)/- 39.5
Venuta and colleagues,10 (2009) 19 105 -/55/47/3 HPP/APP 1 (0.95)/1 44
Galetta and colleagues,13 (2012) 11 47 31/10/4/2 HPP/APP 2 (4.2)/- 39.2
Present study 5 32 -/2/20/10 CAA 1 (2.9)/1 EE and 1 CAA 66
Dashes indicate no conduit was used in these patients. TS, Tangential suture; P, patch; EE, end-to-end anastomosis; C, replacement by conduit; PA, pulmonary artery; HPP, het-
erologous pericardial patch; APP, autologous pericardial patch; CAA, cryopreserved arterial allograft.
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has extended distally beneath the lower lobe segmental
branches, interposition of a cryopreserved allograft
(range, 2-4 cm) provides excellent PA reconstruction. In
this case, it might be recommended to begin with the distal
arterial anastomosis (usually the most difficult because of
the smaller caliber and the need for reimplantation of
segmental branches).
Compared with the report by Rendina and coworkers11 of
52 PA reconstructions with 3 cases of PA replacement
(5.8%), our experience included 10 (31.2%) of the cases.
The more recent nature of our series may explain this higher
rate of PA replacement, because tertiary referral centers
increasingly develop aggressive policies of lung paren-
chymal sparing.3 Our experience of 7 isolated PA replace-
ments after sleeve resections and 3 cases of double-sleeve
resections corroborates another study by Rendina and
coworkers,24 who reported the frequency of PA replacement
(instead of end-to-end anastomosis or patch) in single PA
resection without combined bronchial sleeve resection.
In these cases, the long disease-free bronchial segment
maintains both vascular edges at a far distance, inducing
excessive tensioning of the arterial anastomosis. A forced
end-to-end suture does not allow satisfactory PA recon-
struction and may be responsible for PA or bronchial kink-
ing, with subsequent risk of thrombosis. Moreover, PA
suture performed under tension and with poor visibility of
the arterial stumps, whichmay beweakened by neoadjuvant
CRT, risks hemorrhagic complications or thrombosis.21,25
Early postoperative PA thrombosis after replacement
generally leads to completion pneumonectomy.6,21 Read
and coworkers21 reported on salvage surgical procedures
in 5 of 11 patients, in whom PA reconstruction was
attempted. It seems likely that the nature of the cryopre-
served arterial allograft (thoracic aorta) was responsible
for early thrombosis in patient 4, possibly because of differ-
ences in thickness and/or rigidity between the native PA and
the cryopreserved allograft. Previous studies describing the
use of a cryopreserved allograft in congenital heart surgery
report a high rate of immunogenicity-related graft1196 The Journal of Thoracic and Cardiovascular Surdegeneration at long-term follow-up.26 Likewise, delayed
aneurysms or stenoses when replacing systemic vessels
are occasionally described as an argument against a cryo-
preserved allograft. However, clinically relevant immuno-
genicity or early degeneration has not been observed at
our institution because these allografts were implemented
for replacement of PA or other thoracic vessels.16CONCLUSIONS
Our experience suggests that PA replacement using
cryopreserved arterial allografts for circumferential defects
after extended resection of centrally located NSCLCs is
feasible, with acceptable morbidity. This procedure could
avoid pneumonectomy in selected patients. The few patients
do not permit a comparative study of survival andmorbidity-
mortality; however, the initial results are encouraging.
We thank Alain Wurtz for revision and Elaine M. Lilly for her
contribution to the developmental editing of the manuscript.References
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